Bayer Australia Ltd - Notification - N97583


  • Bayer Australia Ltd

Notification number(s)

  • N97583


Bayer proposes to supply a radiopharmaceutical for the treatment of certain prostate cancer patients (Xofigo), to health centres (including public and private hospitals and other licensed nuclear medicine centres), on condition that the health centre accepts delivery of the product by the Australian Nuclear Science and Technology
Organisation (ANSTO). Because it is a radioactive substance, Xofigo's transportation, storage and administration
is regulated by specific state, territory and federal laws. ANTSO is a Federal government agency which, among other things, supplies nuclear medicine shipments to health centres across Australia.


Document title Date

ACCC correspondence

Document title Date